科美诊断收盘下跌1.58%，滚动市盈率21.64倍，总市值27.48亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, which has a current stock price of 6.85 yuan and a rolling PE ratio of 21.64 times, significantly lower than the industry average of 45.94 times [1][2] - Kemei Diagnostics has a total market capitalization of 2.748 billion yuan and ranks 50th in the medical device industry based on PE ratio [1][2] - As of the third quarter of 2024, Kemei Diagnostics reported a revenue of 344 million yuan, a year-on-year decrease of 0.43%, and a net profit of 112 million yuan, down 6.73% year-on-year, with a gross profit margin of 76.35% [1] Group 2 - The company specializes in the research, development, production, and sales of clinical immunochemical luminescent diagnostic reagents and instruments, being one of the earliest high-tech enterprises in China to focus on this field [1] - Kemei Diagnostics has received several honors, including being recognized as a 2022 Beijing Intellectual Property Demonstration Unit and a 2022 municipal enterprise technology center [1] - A total of 62 institutions hold shares in Kemei Diagnostics, with a combined holding of 2.325 million shares valued at 16 million yuan [1]